OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes $634,000 Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 50,020 shares of the company's stock, valued at approximately $634,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. SG Americas Securities LLC bought a new position in shares of Day One Biopharmaceuticals in the fourth quarter valued at about $866,000. MetLife Investment Management LLC raised its holdings in shares of Day One Biopharmaceuticals by 12.4% in the fourth quarter. MetLife Investment Management LLC now owns 34,248 shares of the company's stock valued at $434,000 after buying an additional 3,781 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its position in Day One Biopharmaceuticals by 90.6% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 121,167 shares of the company's stock worth $1,535,000 after purchasing an additional 57,601 shares during the period. Charles Schwab Investment Management Inc. increased its position in Day One Biopharmaceuticals by 5.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 535,501 shares of the company's stock worth $6,785,000 after purchasing an additional 28,053 shares during the period. Finally, Bank of New York Mellon Corp increased its position in Day One Biopharmaceuticals by 43.4% in the fourth quarter. Bank of New York Mellon Corp now owns 244,829 shares of the company's stock worth $3,102,000 after purchasing an additional 74,091 shares during the period. 87.95% of the stock is owned by institutional investors.

Day One Biopharmaceuticals Price Performance

Shares of DAWN traded up $0.13 during mid-day trading on Monday, hitting $6.38. The stock had a trading volume of 570,032 shares, compared to its average volume of 1,103,089. Day One Biopharmaceuticals, Inc. has a 52 week low of $6.08 and a 52 week high of $16.76. The firm has a market cap of $647.10 million, a P/E ratio of -6.16 and a beta of -1.24. The business has a fifty day moving average price of $7.44 and a 200-day moving average price of $10.77.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.46) by $0.11. The company had revenue of $30.76 million for the quarter, compared to the consensus estimate of $30.28 million. As a group, research analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.

Insider Transactions at Day One Biopharmaceuticals

In related news, CEO Jeremy Bender sold 12,048 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $144,094.08. Following the completion of the sale, the chief executive officer now owns 128,015 shares of the company's stock, valued at $1,531,059.40. The trade was a 8.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel Adam Dubow sold 4,646 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $55,566.16. Following the sale, the general counsel now directly owns 39,602 shares of the company's stock, valued at approximately $473,639.92. This represents a 10.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 21,064 shares of company stock worth $251,925. 6.20% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

DAWN has been the subject of a number of research reports. The Goldman Sachs Group lowered their price objective on Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating for the company in a research report on Tuesday, March 25th. Needham & Company LLC cut their target price on Day One Biopharmaceuticals from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Wedbush restated an "outperform" rating and issued a $25.00 target price on shares of Day One Biopharmaceuticals in a research note on Wednesday, May 7th. HC Wainwright reiterated a "buy" rating and set a $36.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, April 3rd. Finally, JPMorgan Chase & Co. dropped their price objective on Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating on the stock in a research note on Wednesday, March 5th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $30.57.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.